XML 25 R9.htm IDEA: XBRL DOCUMENT
v3.19.1

REVERSE MERGER | 12 Months Ended
--- | ---
Dec. 31, 2018
REVERSE MERGER [Abstract] |
REVERSE MERGER | 3. REVERSE MERGER On June 29, 2017 (the “Closing Date”), the Company completed the Merger with Precipio Diagnostics, in accordance with the terms of the Merger Agreement. On the closing date of the Merger, the outstanding common and preferred units of Precipio Diagnostics and certain debt of Precipio Diagnostics were converted into (i) 5,352,847 shares of Precipio common stock, together with cash in lieu of fractional units, and (ii) 802,920 shares of Precipio preferred stock with an aggregate face amount equal to $3 million. Upon the consummation of the Merger, the historical financial statements of Precipio Diagnostics became the Company’s historical financial statements. In connection with the Merger, on the closing date, Precipio also issued promissory notes and shares of Precipio preferred and common stock in a number of transactions, whereby:
| · |  | Holders of certain secured indebtedness of Transgenomic received in exchange for such indebtedness 802,925 shares of Precipio preferred stock in an amount equal to $3.0 million stated value, and 352,630 shares of Precipio common stock;
| · |  | Holders of Transgenomic preferred stock converted it into 7,155 shares of Precipio common stock; and
| · |  | Precipio issued 107,056 shares of Precipio preferred stock to certain investors in exchange for $400,000 in a private placement. Precipio also completed the sale of an aggregate of $800,000 of promissory notes pursuant to a securities purchase agreement.
Purchase Consideration The estimated purchase consideration based on the value of the equity of Transgenomic, the accounting acquiree, is as follows:
(dollars in thousands) |  |  |
Legacy Transgenomic common stock |  | $ | 6,088
Fair value of preferred stock converted to common stock |  |  | 49
Fair value of debt converted to common stock |  |  | 2,398
Fair value of debt converted to preferred stock |  |  | 9,796
Fair value of existing bridge notes |  |  | 1,275
Fair value of warrants |  |  | 1,996
Purchase consideration |  | $ | 21,602
In estimating the purchase consideration above, Transgenomic used its closing stock price of $6.80 as of the Closing Date. Transgenomic had 895,334 common shares outstanding prior to the Merger. In connection with the Merger, Transgenomic preferred stock converted into 7,155 shares of Precipio common stock and certain of Transgenomic debt and accrued interest converted into 352,630 shares of Precipio common stock and 802,925 shares of Precipio preferred stock, face value $3.0 million with an 8% annual dividend. At the Closing Date, the preferred stock had a fair value of $12.20 per share. Allocation of Purchase Consideration The following table sets forth an allocation of the purchase consideration to the identifiable tangible and intangible assets of Transgenomic, the accounting acquiree, based on fair values as of the Closing Date with the excess recorded as goodwill:
(dollars in thousands) |  |  |
Current and other assets |  | $ | 419
Property and equipment |  |  | 29
Goodwill |  |  | 14,000
Other intangible assets(1) |  |  | 21,100
Total assets |  |  | 35,548
Current liabilities |  |  | 13,423
Other liabilities |  |  | 523
Total liabilities |  |  | 13,946
Net assets acquired |  | $ | 21,602
| (1) |  | Other intangible assets consist of:
(dollars in thousands) |  |  |
Acquired technology |  | $ | 18,990
Customer relationships |  |  | 250
Non-compete agreements |  |  | 30
Trademark and trade name |  |  | 40
Backlog |  |  | 200
In-process research and development |  |  | 1,590
Total intangibles |  | $ | 21,100
We determined the estimated fair value of the acquired technology by using the multi-period excess earnings method of the income approach. The estimated fair value of the remaining identifiable intangible assets acquired were determined primarily by using the income approach. Unaudited pro forma information The operating results of Transgenomic have been included in the Company’s consolidated financial statements for all periods after June 29, 2017. The following unaudited pro forma information presents the Company’s financial results as if the acquisition of Transgenomic had occurred on January 1, 2017 and combines Transgenomic’s unaudited consolidated statement of operations for the period from January 1, 2017 through June 29, 2017 with Precipio’s statement of operations for the year ended December 31, 2017:
|  | For the Year Ended December 31,
Dollars in thousands, except per share amounts |  | 2017
Net sales |  | $ | 2,687
Net loss available to common stockholders |  |  | (37,389)
Loss per common share |  | $ | (4.95)

X
- Definition The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -URI http://asc.fasb.org/topic&trid=2303972 + Details
Name: | us-gaap_BusinessCombinationDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_BusinessCombinationsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration